Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
STT enters its October 14 earnings print with a stock down 10% over the past month, a cluster of analysts cutting price targets this week, and short interest running 24% above its level a month ago.
The most interesting tension here is not the magnitude of bearish positioning but the direction. Short interest at 1.9% of the free float is not large by any measure. But the pace of accumulation is notable. Shorts have added roughly 24% to their position over the past 30 days, with the week-on-week reading also up 3.9%. The stock's ORTEX short score sits at 31.9, consistent with the past week's range. That score puts STT in the 67th percentile on the short score rank, not alarming in absolute terms but worth tracking given the build. The borrow market tells a completely different story: availability is essentially unlimited, with more than 218 million shares available to lend against roughly 5.3 million shares currently short. Borrowing costs have actually fallen 17% on the week to 0.33%. Nothing in the lending market suggests a squeeze dynamic. The short build looks like a deliberate pre-earnings hedge, not a structural conviction trade.
Options positioning has shifted away from the defensive stance seen through much of September. The put/call ratio has eased to 0.88, below its 20-day average of 0.95 and around one standard deviation lighter on hedges than that recent norm. In September, the PCR was consistently above 1.0, touching a recent peak above 1.17. The step-down coincides with the stock's month-long slide, which may mean some of that protection has already been monetised or has simply expired.
The Street went into earnings week in several directions at once. TD Cowen reinstated coverage this week with a Buy and a $205 target. Citi lifted its target slightly to $212, also with a Buy. On the other side, BMO cut its target from $212 to $200 while keeping Outperform, and Truist trimmed to $190 on a Hold rating. JPMorgan, sitting at Neutral, edged its target up fractionally to $187.50. The consensus remains Buy, but the recent pattern is one of bulls shaving targets and bears staying cautious rather than any firm turning more aggressive in either direction. The valuation picture has compressed: the price-to-earnings multiple has dropped by roughly 1.4 turns over the past 30 days to 11.6x, and price-to-book has shed almost 0.19 points to 1.76x. At those levels the stock is not demanding, but the multiple compression also reflects the 10% price decline rather than any change in underlying earnings estimates. Factor scores offer a mixed read: EPS momentum over 90 days ranks at the 87th percentile, EPS surprise at the 76th, both genuine positives. But the 12-month forward EPS year-on-year increase sits only at the 45th percentile, suggesting the growth-versus-consensus story is less compelling further out.
The bull case rests on the franchise's scale. AUC/A of $57.9 trillion and AUM of $6.3 trillion provide durable fee-based revenue that is difficult to replicate. The last quarterly print showed 17% revenue growth and 44% EPS growth on an ex-notables basis, with 25.5% ROTCE and a 645 basis point positive operating leverage gap. The bear case focuses on the edges: software services revenue fell both sequentially and year-on-year, securities finance dropped 8.7%, and provisions for credit losses are moving higher. The concern is that asset-value sensitivity to equity market volatility, particularly with AUM already slipping from $5.7 trillion to $5.6 trillion in recent quarters, creates a revenue ceiling that rising costs could eat through.
The FDIC call report data covering STT's insured bank charters shows net income for the quarter ended April 2026 running 60% above the same period a year earlier, reaching $1.115 billion. Net loans and leases have risen for three consecutive quarters to $52.2 billion. ORTEX has not yet measured whether this dataset leads the company's reported figures, so these readings offer colour on the underlying bank subsidiary rather than a directional read on the October 14 print.
Insider activity since July has been net negative, with the CEO, Chief Risk Officer, and Chief Accounting Officer all recording open-market sales. The CEO's two sales totalling roughly $3.1 million were both conducted under pre-arranged 10b5-1 plans, which reduces their informational value. The net 90-day figure across all insider transactions stands at roughly minus 37,000 shares worth approximately $6.7 million. BlackRock recently added around 392,000 shares to bring its stake to 8.9% of shares outstanding, while FMR (Fidelity) added 2.18 million shares to reach 4.5%. No activist 13D filings are on the register.
Closest peers have also had a difficult week. BNY fell 1.3% on the week and GS dropped 1.5%, while NTRS slipped 0.7% and MS managed a small gain of 0.9%. The sector-wide drift lower provides some cover for STT's own decline, making the October 14 print the cleaner test of whether the share price has moved enough ahead of results to reset expectations.
The key question heading into Tuesday's report is whether management's fee revenue and NII guidance upgrades from last quarter can survive a month that has seen equity markets under pressure, or whether the cost-side and software-revenue pressures the bears have flagged will narrow the positive operating leverage gap that drove the stock's earlier 2026 re-rating.
See the live data behind this article on ORTEX.
Open STT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
